Clinical Outcomes and Prognostic Features of Diffuse Hemispheric Glioma, H3 G34-mutant: An International Multi-Institutional Study - PubMed
3 days ago
- #prognosis
- #oncology
- #glioma
- Study investigates prognostic factors for diffuse hemispheric glioma, H3 G34-mutant (DHG, H3 G34).
- 153 patients included (142 G34R, 9 G34V, 2 via DNA methylation), median age at diagnosis was 17 years.
- 43% of patients achieved initial gross/near total resection (GTR/NTR).
- 91% received radiation (85% focal irradiation), 87% received initial chemotherapy (70% temozolomide-based).
- Median overall survival (OS) was 24 months, median progression-free survival (PFS) was 14 months.
- 8% of patients were long-term survivors (≥5 years).
- Adjuvant radiation therapy and GTR/NTR were associated with improved PFS.
- Improved OS linked to increasing age at diagnosis, initial radiation therapy, and GTR/NTR.
- Highlights need for clinical trials and prospective registries to improve outcomes.